{"DataElement":{"publicId":"2797724","version":"1","preferredName":"Radiation Therapy Oncology Group Patient Inclusion Clinical Trial Eligibility Criteria 0825 Type","preferredDefinition":"the type of element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"RTOG_PT_I_CT_0825_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2797715","version":"1","preferredName":"Radiation Therapy Oncology Group Patient Inclusion Criteria Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"RTOG_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2660517","version":"1","preferredName":"Radiation Therapy Oncology Group Patient","preferredDefinition":"The Radiation Therapy Oncology Group (RTOG) is a multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient:A person who requires medical care.","longName":"C19778:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy Oncology Group","conceptCode":"C19778","definition":"A multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E5C497-F142-4C81-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF72E80-5722-55DB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2797723","version":"1","preferredName":"0825 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for a Radiation Therapy Oncology Group 0825 protocol.","longName":"0825_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Was the patient diagnosed with recurrance or progression (must be diagnosed by imaging only)","valueDescription":"Was the patient diagnosed with recurrance or progression (must be diagnosed by imaging only)","ValueMeaning":{"publicId":"2797725","version":"1","preferredName":"Was the patient diagnosed with recurrance or progression (must be diagnosed by imaging only)","longName":"2797725","preferredDefinition":"Was the patient diagnosed with recurrance or progression (must be diagnosed by imaging only)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6C4C9-A664-6EA0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6C9B6-FE2A-70F0-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Has the patient received any chemotherapy, radiotherapy, or other treatment intended as an anti-cancer therapy since the protocol based treatment (RT, temozolomide +/- bevacizumab/placebo) on the blinded component of the study","valueDescription":"Has the patient received any chemotherapy, radiotherapy, or other treatment intended as an anti-cancer therapy since the protocol based treatment (RT, temozolomide +/- bevacizumab/placebo) on the blinded component of the study","ValueMeaning":{"publicId":"2797726","version":"1","preferredName":"Has the patient received any chemotherapy, radiotherapy, or other treatment intended as an anti-cancer therapy since the protocol based treatment (RT, temozolomide +/- bevacizumab/placebo) on the blinded component of the study","longName":"2797726","preferredDefinition":"Has the patient received any chemotherapy, radiotherapy, or other treatment intended as an anti-cancer therapy since the protocol based treatment (RT, temozolomide +/- bevacizumab/placebo) on the blinded component of the study","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6C679-0752-6536-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6C9B6-FE3C-70F0-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Has the patient undergone resection of the recurrent tumor/tumors","valueDescription":"Has the patient undergone resection of the recurrent tumor/tumors","ValueMeaning":{"publicId":"2797727","version":"1","preferredName":"Has the patient undergone resection of the recurrent tumor/tumors","longName":"2797727","preferredDefinition":"Has the patient undergone resection of the recurrent tumor/tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6C9B6-FE13-70F0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6C9B6-FE4E-70F0-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Has the patient recovered from the effects of surgery, postoperative infection, and other complications","valueDescription":"Has the patient recovered from the effects of surgery, postoperative infection, and other complications","ValueMeaning":{"publicId":"2797728","version":"1","preferredName":"Has the patient recovered from the effects of surgery, postoperative infection, and other complications","longName":"2797728","preferredDefinition":"Has the patient recovered from the effects of surgery, postoperative infection, and other complications","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6CB46-E08D-6C66-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6C9B6-FE60-70F0-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Was an MRI or CT scan obtained that demonstrates the following: postoperative hemorrhage defined as > 1 cm diameter of blood (if > 1 cm of acute blood is detected, the patient may not receive unblinded bevacizumab)","valueDescription":"Was an MRI or CT scan obtained that demonstrates the following: postoperative hemorrhage defined as > 1 cm diameter of blood (if > 1 cm of acute blood is detected, the patient may not receive unblinded bevacizumab)","ValueMeaning":{"publicId":"2797729","version":"1","preferredName":"Was an MRI or CT scan obtained that demonstrates the following: postoperative hemorrhage defined as > 1 cm diameter of blood (if > 1 cm of acute blood is detected, the patient may not receive unblinded bevacizumab)","longName":"2797729","preferredDefinition":"Was an MRI or CT scan obtained that demonstrates the following: postoperative hemorrhage defined as > 1 cm diameter of blood (if > 1 cm of acute blood is detected, the patient may not receive unblinded bevacizumab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6B9EB-512E-709B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6C9B6-FE72-70F0-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Is the Karnofsky performance status > 60","valueDescription":"Is the Karnofsky performance status > 60","ValueMeaning":{"publicId":"2797730","version":"1","preferredName":"Is the Karnofsky performance status > 60","longName":"2797730","preferredDefinition":"Is the Karnofsky performance status > 60","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6D069-AE59-6C7E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6DAAE-0F1E-6C7C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Is there adequate bone marrow function defined as follows Absolute neutrophil count (ANC) >= 1,500 cells/mm^3; Platelets >= 100,000 cells/mm^3; Hemoglobin >= 10.0 g/dl (Note: The use of transfusion or other intervention is acceptable)","valueDescription":"Is there adequate bone marrow function defined as follows Absolute neutrophil count (ANC) >= 1,500 cells/mm^3; Platelets >= 100,000 cells/mm^3; Hemoglobin >= 10.0 g/dl (Note: The use of transfusion or other intervention is acceptable)","ValueMeaning":{"publicId":"2797731","version":"1","preferredName":"Is there adequate bone marrow function defined as follows Absolute neutrophil count (ANC) >= 1,500 cells/mm^3; Platelets >= 100,000 cells/mm^3; Hemoglobin >= 10.0 g/dl (Note: The use of transfusion or other intervention is acceptable)","longName":"2797731","preferredDefinition":"Is there adequate bone marrow function defined as follows Absolute neutrophil count (ANC) >= 1,500 cells/mm^3; Platelets >= 100,000 cells/mm^3; Hemoglobin >= 10.0 g/dl (Note: The use of transfusion or other intervention is acceptable)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6D33E-2E37-70DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6DAAE-0F30-6C7C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Is there adequate renal function, as defined below BUN <= 30 mg/dl; Creatinine <= 1.7 mg/dl; Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio. For UPC ratio > 0.5, 24-hour urine protein should be obtained","valueDescription":"Is there adequate renal function, as defined below BUN <= 30 mg/dl; Creatinine <= 1.7 mg/dl; Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio. For UPC ratio > 0.5, 24-hour urine protein should be obtained","ValueMeaning":{"publicId":"2797732","version":"1","preferredName":"Is there adequate renal function, as defined below BUN <= 30 mg/dl; Creatinine <= 1.7 mg/dl; Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio. For UPC ratio > 0.5, 24-hour urine protein should be obtained","longName":"2797732","preferredDefinition":"Is there adequate renal function, as defined below BUN <= 30 mg/dl; Creatinine <= 1.7 mg/dl; Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio. For UPC ratio > 0.5, 24-hour urine protein should be obtained","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6BF53-4021-722C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6DAAE-0F42-6C7C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Is there adequate hepatic function, as defined below Bilirubin <= 2.0 mg/dl; ALT/AST <= 3 x normal range","valueDescription":"Is there adequate hepatic function, as defined below Bilirubin <= 2.0 mg/dl; ALT/AST <= 3 x normal range","ValueMeaning":{"publicId":"2797733","version":"1","preferredName":"Is there adequate hepatic function, as defined below Bilirubin <= 2.0 mg/dl; ALT/AST <= 3 x normal range","longName":"2797733","preferredDefinition":"Is there adequate hepatic function, as defined below Bilirubin <= 2.0 mg/dl; ALT/AST <= 3 x normal range","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6D7B1-A229-6CB9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6DAAE-0F54-6C7C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Is the prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing","valueDescription":"Is the prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing","ValueMeaning":{"publicId":"2797734","version":"1","preferredName":"Is the prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing","longName":"2797734","preferredDefinition":"Is the prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6D9C7-B3F1-6B88-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6DAAE-0F66-6C7C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Is the patient on full-dose anticoagulants (e.g., warfarin or LMW heparin)","valueDescription":"Is the patient on full-dose anticoagulants (e.g., warfarin or LMW heparin)","ValueMeaning":{"publicId":"2797735","version":"1","preferredName":"Is the patient on full-dose anticoagulants (e.g., warfarin or LMW heparin)","longName":"2797735","preferredDefinition":"Is the patient on full-dose anticoagulants (e.g., warfarin or LMW heparin)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6DC71-0233-6C6C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6BF53-4038-722C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"If on full dose anticoagulants, have both of the following criteria been met No active bleeding or pathological condition that carries a high risk of bleeding; In-range INR on a stable dose of oral anticoagulant","valueDescription":"If on full dose anticoagulants, have both of the following criteria been met No active bleeding or pathological condition that carries a high risk of bleeding; In-range INR on a stable dose of oral anticoagulant","ValueMeaning":{"publicId":"2797736","version":"1","preferredName":"If on full dose anticoagulants, have both of the following criteria been met No active bleeding or pathological condition that carries a high risk of bleeding; In-range INR on a stable dose of oral anticoagulant","longName":"2797736","preferredDefinition":"If on full dose anticoagulants, have both of the following criteria been met No active bleeding or pathological condition that carries a high risk of bleeding; In-range INR on a stable dose of oral anticoagulant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6B9EB-513E-709B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6BF53-404A-722C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"For females of childbearing potential was a negative serum pregnancy test done","valueDescription":"For females of childbearing potential was a negative serum pregnancy test done","ValueMeaning":{"publicId":"2797737","version":"1","preferredName":"For females of childbearing potential was a negative serum pregnancy test done","longName":"2797737","preferredDefinition":"For females of childbearing potential was a negative serum pregnancy test done","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6E0CC-75B2-70A5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6BF53-405C-722C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Is systolic blood pressure <=160 mg hg or diastolic pressure <= 90 mg hg","valueDescription":"Is systolic blood pressure <=160 mg hg or diastolic pressure <= 90 mg hg","ValueMeaning":{"publicId":"2797738","version":"1","preferredName":"Is systolic blood pressure <=160 mg hg or diastolic pressure <= 90 mg hg","longName":"2797738","preferredDefinition":"Is systolic blood pressure <=160 mg hg or diastolic pressure <= 90 mg hg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6E0CC-75C2-70A5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6BF53-406E-722C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Is the electrocardiogram without evidence of acute cardiac ischemia","valueDescription":"Is the electrocardiogram without evidence of acute cardiac ischemia","ValueMeaning":{"publicId":"2797739","version":"1","preferredName":"Is the electrocardiogram without evidence of acute cardiac ischemia","longName":"2797739","preferredDefinition":"Is the electrocardiogram without evidence of acute cardiac ischemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6E0CC-75D2-70A5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6BF53-4080-722C-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"},{"value":"Planned start date for salvage treatment","valueDescription":"Planned start date for salvage treatment","ValueMeaning":{"publicId":"2797740","version":"1","preferredName":"Planned start date for salvage treatment","longName":"2797740","preferredDefinition":"Planned start date for salvage treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6E646-1A61-6C73-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AF6E6DA-E0B2-6C80-E044-0003BA3F9857","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF6B9EB-5116-709B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811949","version":"1","longName":"Brain","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Inclusion Criteria","type":"Preferred Question Text","description":"Inclusion Criteria","url":null,"context":"CTEP"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"5AF6BB64-B58F-6C6F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-05","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}